TRIPLE G 10 mg

One-Peptides Triple G 10 mg – GLP-1/GIP/glucagon tri-agonist peptide for research

In July 2023, The New England Journal of Medicine published phase II data on retatrutide (LY3437943), an Eli Lilly peptide that reported a weight reduction of 24,2% in adults with obesity (Jastreboff et al., 2023). The fundamental evolutionary step is here third receptor: addition of activity on the glucagon receptor (GCGR) to the existing dual combination of GLP-1R + GIPR.

Triple G is a research grade peptide incretin tri-agonists — a molecule that simultaneously activates three metabolic axis receptors. Structurally and mechanistically related retatrutide, remains in the One Peptides catalog as a chemical reagent for laboratory research on the pharmacology of incretin receptors. It is not a medicine. All reference results are derived from experimental literature on related molecules. A complete review of the class of incretin peptides is described a guide to GLP-1 peptides in metabolism research.

Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for administration to humans or animals outside a controlled experimental environment.

Regulatory frame – drug vs RUO. Triple G is not the same as registered incretin drugs. Semaglutide (Ozempic, Wegovy) is a GLP-1R mono-agonist approved by the EMA and FDA. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1R + GIPR agonist, also approved. Retatrutide (Eli Lilly LY3437943) is a GLP-1R + GIPR + GCGR tri-agonist, currently in phase III of the TRIUMPH trial, without registration as a medicine in either the EU or the USA. Triple G in the One Peptides catalog is an RUO reagent for research on the incretin axis – not a medicinal form, not a therapeutic analogue for use in humans.

What is Triple G – Pharmacological Class

Triple G belongs to incretin receptor tri-agonists — the third generation of metabolic pharmacology peptides, after mono-agonists (semaglutide) and dual-agonists (tirzepatide). The molecule simultaneously activates three G protein-coupled receptors: GLP-1R, GIPR and GCGR. Structural and mechanistic relatedness connects it with retatrutide (LY3437943) — the most clinically advanced peptide of the class, first described in the work of Coskun et al. (2022).

The informal shorthand used for retatrutide in online searches is explained in a separate entry: the term “reta” in the context of retatrutide.

Solid peptide phase synthesis (SPPS) with purifying HPLC. The molecule introduces modifications typical of modern incretin analogues — acylation with a fatty acid chain enabling reversible binding to albumin, which extends the half-life. In retatrutide clinical protocols, this allows for once weekly administration.

Chemical characteristics

The exact sequence of the research peptide in the catalog depends on the specific batch and is documented in the Certificate of Analysis (COA) issued for each batch.

Mechanism – Why triple activation?

The tri-agonist philosophy arises from the observation that three incretin axis hormones act at different levels of metabolism – and their simultaneous pharmacological activation produces a synergistic effect that is impossible to achieve with mono-receptor targeting. Each trail makes a different contribution. Complete physiology of the three receptors in article about the incretins GLP-1, GIP and glucagon.

GLP-1R (glucagon-like peptide receptor 1). Activation increases glucose-dependent insulin secretion (without the risk of hypoglycemia), inhibits postprandial glucagon secretion, slows gastric emptying, and reduces appetite through a central action in the hypothalamus. The same axis is responsible for pharmacology semaglutide.

GIPR (glucose-dependent insulinotropic peptide receptor). The addition of GIPR-agonism brings about an incretin effect – a synergistic increase in insulin secretion during glucose loading and modulation of adipose tissue metabolism. Improved gastrointestinal tolerance has been reported in preclinical models. Tirzepatide is based on the combination of GLP-1R + GIPR.

GCGR (glucagon receptor). An evolutionarily new element. In classical endocrinology, glucagon is associated with the mobilization of glucose from the liver – an action that seems to be contrary to the goal of diabetes therapy. In tri-agonist pharmacology, GCGR-agonism plays a different role: increases energy expenditure, induces thermogenesis in brown tissue, intensifies lipolysis in the liver and adipose tissue. In preclinical models, it has been reported that the addition of GCGR to a dual-agonist enhances visceral fat reduction and improves liver parameters in MASLD/MASH models.

The synergy of the three pathways is reported in the literature as providing a greater reduction in body weight and a deeper normalization of metabolic parameters than mono- and dual-agonists. Reference data comes from work on retatrutide (Coskun et al. 2022; Jastreboff et al. 2023; Rosenstock et al. 2023).

Position in the classification of incretin peptides

The incretin peptide landscape is divided into three generations according to the number of activated receptors. The table organizes the regulatory status and pharmacological class.

The table highlights a fundamental regulatory distinction: only molecules from the mono- and dual-agonist groups have drug status. Tri-agonists – including retatrutide as the most clinically advanced representative of the class – remain in the clinical trial phase. Triple G in the One Peptides catalog functions in a separate regulatory frame as research reagent Research Use Only, not a clinical analogue or human administration form.

Applications in scientific research

Triple G as a research reagent is used in experimental work in several directions.

Pharmacology of the incretin axis. Analyzes of receptor activity, GLP-1R/GIPR/GCGR selectivity profiling, EC50 measurements in cell cultures with cAMP and β-arrestin signaling reporters.

Animal models of insulin resistance and obesity. DIO mice, ob/ob and db/db models, Zucker rats. Endpoints: body weight, composition (DEXA, NMR), OGTT/ITT, HOMA-IR, lipid profile.

MASLD/MASH models. Liver steatosis and fibrosis – an area where triple activation with added GCGR-agonism showed the greatest advantage over dual-agonists. CDAA-HFD and GAN-diet models for assessing hepatic triglyceride reduction.

Pharmacokinetics and structural analyses. PK/PD profile of acylated analogues, kinetics of binding to albumin, tissue distribution. Reference material for SAR work and molecular modeling of the next generations of incretin analogues.

One Peptides quality specification

Each batch of Triple G in the One Peptides catalog undergoes an analytical control process. A batch that does not meet any of these rules does not leave the warehouse.

• HPLC ≥98% — purity verified by high-performance liquid chromatography; main peak area ≥98% of sum of areas.
• MS confirmation — confirmation of structural identity by mass spectrometry.
• COA per batch — public certificate of analysis for each batch (theoretical/measured weight, HPLC, date of synthesis, batch number).
• Cold chain 2–8°C — cold chain with monitoring from synthesis to delivery.
• Batch traceability — batch number in three places: label, invoice, COA.

Details of the QA process, sample COAs, and descriptions of each of the five audit stages – v quality tests and certificates.

Reconstitution protocol

The following guide describes the general procedure for preparing a working solution from lyophilized food in the context of a laboratory research reagent. It does not constitute a dosage for humans or animals – it is only a technical guide for reconstituting the reagent for further experimental work.

Solvent. Standard bacteriostatic water (sterile water with 0.9% benzyl alcohol) or sterile water for injection. For cell cultures – PBS buffer with pH 7.4.

Solvent volume. Typical 1–2 mL per 10 mg vial. 1 mL gives a concentration of 10 mg/mL, 2 mL – 5 mg/mL.

Working concentrations. Work on incretin analogues ranges from the picomolar scale in in vitro receptor tests to the microgram per kilogram mass in animal models. Working solutions are prepared by serial dilution.

Procedure. For a full step-by-step guide, see the article how to dissolve peptides. Pour the solvent slowly along the side of the vial. Leave in an upright position for 1-2 minutes, then gently roll in your hands (do not shake – acylated peptides are sensitive to foam). The solution should be clear.

Stability. Unopened lyophilisate: at least 24 months at -20°C, protected from light. Solution after reconstitution in bacteriostatic water – for 28 days at 2–8°C. Avoid freeze-thaw cycles.

Peptide calculator will help you calculate the exact amount of solvent for the planned concentration of the starting solution.

Regulatory status – Triple G, retatrutide, semaglutide

The regulatory landscape of the tri-agonist class requires precise separation of the three frames.

Triple G in the One Peptides catalog to chemical reagent Research Use Only. Under EU pharmaceutical law, it is not a medicinal product, dietary supplement or food. It is not authorized by EMA or any national registration authority. It is also not registered as a drug in the US, UK, Canada or Australia.

Retatrutide (LY3437943) — the most clinically advanced GLP-1R/GIPR/GCGR tri-agonist — remains in phase III of the TRIUMPH trial run by Eli Lilly. Phase II data were published in 2023 in NEJM (obesity) and Lancet (type 2 diabetes). Without registration as a doctor.

Only mono- and dual-agonists have drug status. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are registered medicinal products. Triple G does not fall into this category – it is not “GLP-1 for weight loss”, it is not a diabetes drug, it is not a therapeutic analogue. This is a reagent for research on the mechanisms of the incretin axis.

The WADA status of peptides in this class is not directly listed in the current list – it is the investigator’s responsibility to verify current guidelines.

Triple G FAQs

How is Triple G different from retatrutide?

Both peptides represent the same pharmacological class – GLP-1R + GIPR + GCGR tri-agonists. Retatrutide (LY3437943) is a specific Eli Lilly molecule with published Phase II data and an ongoing Phase III. Triple G is a research peptide from the same class in the RUO reagent catalog. Mechanism reference data comes from the literature on retatrutide.

Is Triple G a weight loss drug?

NO. Triple G is not a drug or therapeutic analogue. This is a Research Use Only chemical reagent for laboratory tests. Incretin axis drugs registered in the EU are only semaglutide (mono-agonist) and tirzepatide (dual-agonist) – no molecule from the tri-agonist group, including retatrutide in phase III, is registered as a drug.

Why is triple activation more powerful than dual-agonist (tirzepatide)?

The addition of GCGR-agonism brings a mechanism not present in dual-agonists — increasing energy expenditure and intensification of lipolysis in the liver. In preclinical and Phase II models, retatrutide reported greater weight reduction than tirzepatide over a comparable time frame. Fully assessing the safety profile of tri-agonists in long-term Phase III studies remains the subject of ongoing TRIUMPH work.

Is Triple G registered as a medicine in the EU?

NO. Triple G does not have a marketing authorization in the EU. Functions as a Research Use Only chemical reagent. The entire class of incretin tri-agonists is currently outside the scope of EMA-registered drugs.

How does Triple G compare to semaglutide (Ozempic)?

Triple G and semaglutide represent different classes incretin pharmacology. Semaglutide is a GLP-1R mono-agonist – it activates one receptor. Triple G is a tri-agonist – it activates three receptors in parallel. Semaglutide is a registered drug (Ozempic, Wegovy, Rybelsus). Triple G is an RUO research reagent with no drug status.

What is the WADA status of this class of peptides?

Incretin receptor tri-agonists are not listed directly on the current WADA list. The status may change in subsequent editions – it is the researcher’s responsibility to verify the current guidelines.

Bibliography

1. Jastreboff AM et al (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial
2. Coskun T et al (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
3. Rosenstock J et al (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
4. Frias JP et al (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
5. Nahra R et al (2021). Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

Chemical reagent Research Use Only. Triple G in the One Peptides catalog is not a medicinal product, dietary supplement or food. It is not intended for administration to humans or animals outside a controlled experimental environment. Triple G should not be confused with incretin medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) or retatrutide in phase III clinical trials. The information in the description is of an educational and scientific nature and concerns results reported in experimental literature – it does not constitute medical advice or a suggestion for clinical use.